AU2018298881B2 - Improved dual specificity polypeptide molecule - Google Patents
Improved dual specificity polypeptide molecule Download PDFInfo
- Publication number
- AU2018298881B2 AU2018298881B2 AU2018298881A AU2018298881A AU2018298881B2 AU 2018298881 B2 AU2018298881 B2 AU 2018298881B2 AU 2018298881 A AU2018298881 A AU 2018298881A AU 2018298881 A AU2018298881 A AU 2018298881A AU 2018298881 B2 AU2018298881 B2 AU 2018298881B2
- Authority
- AU
- Australia
- Prior art keywords
- ser
- val
- gly
- leu
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| US62/532,713 | 2017-07-14 | ||
| DE102017115966.5 | 2017-07-14 | ||
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017119866 | 2017-08-30 | ||
| DE102017119866.0 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| DE102018108995.3 | 2018-04-16 | ||
| DE102018108995 | 2018-04-16 | ||
| US62/658,318 | 2018-04-16 | ||
| PCT/EP2018/069151 WO2019012138A1 (en) | 2017-07-14 | 2018-07-13 | POLYPEPTIDE MOLECULE WITH IMPROVED DOUBLE-SPECIFICITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018298881A1 AU2018298881A1 (en) | 2020-01-16 |
| AU2018298881B2 true AU2018298881B2 (en) | 2025-04-17 |
Family
ID=62951983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018298884A Abandoned AU2018298884A1 (en) | 2017-07-14 | 2018-07-13 | Improved dual specificity polypeptide molecule |
| AU2018298881A Active AU2018298881B2 (en) | 2017-07-14 | 2018-07-13 | Improved dual specificity polypeptide molecule |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018298884A Abandoned AU2018298884A1 (en) | 2017-07-14 | 2018-07-13 | Improved dual specificity polypeptide molecule |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US11905328B2 (enExample) |
| EP (3) | EP3985029A1 (enExample) |
| JP (4) | JP2020530762A (enExample) |
| KR (2) | KR20200026995A (enExample) |
| CN (2) | CN110914308A (enExample) |
| AU (2) | AU2018298884A1 (enExample) |
| BR (2) | BR112020000769A2 (enExample) |
| CA (2) | CA3069842A1 (enExample) |
| CO (2) | CO2020001029A2 (enExample) |
| CR (2) | CR20200013A (enExample) |
| CY (2) | CY1124091T1 (enExample) |
| DK (2) | DK3652215T3 (enExample) |
| ES (2) | ES2898210T3 (enExample) |
| HR (1) | HRP20211744T1 (enExample) |
| HU (2) | HUE057110T2 (enExample) |
| LT (2) | LT3652215T (enExample) |
| MA (1) | MA46299B1 (enExample) |
| MD (2) | MD3428194T2 (enExample) |
| MX (1) | MX2020011744A (enExample) |
| PE (2) | PE20200615A1 (enExample) |
| PL (2) | PL3652215T3 (enExample) |
| PT (2) | PT3428194T (enExample) |
| RS (2) | RS61817B1 (enExample) |
| SG (2) | SG11202000025SA (enExample) |
| SI (2) | SI3428194T1 (enExample) |
| TW (2) | TWI762677B (enExample) |
| WO (2) | WO2019012138A1 (enExample) |
| ZA (1) | ZA202000842B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| LT3652215T (lt) | 2017-07-14 | 2021-05-25 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| BR112020023195A2 (pt) | 2018-05-14 | 2021-09-28 | Immunocore Limited | Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的高亲和力tcr |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| JP7738914B2 (ja) * | 2019-12-05 | 2025-09-16 | アーベル リミテッド | ＴｒｉＡｘ抗体の組成、その製造方法及び使用方法 |
| BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| MX2024001179A (es) | 2021-07-27 | 2024-02-27 | Immatics Biotechnologies Gmbh | Proteinas de union a antigenos que se unen especificamente a ct45. |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| UY39967A (es) | 2021-10-06 | 2023-05-15 | Immatics Biotechnologies Gmbh | Indicaciones para los aglutinantes anti-PRAME |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| EP4448570A1 (en) * | 2021-12-14 | 2024-10-23 | CDR-Life AG | Dual mhc-targeting t cell engager |
| CA3250782A1 (en) | 2022-02-20 | 2023-08-24 | Immunocore Limited | HIV-SPECIFIC BINDING MOLECULES AND TCR |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023209124A1 (en) * | 2022-04-29 | 2023-11-02 | Immatics Biotechnologies Gmbh | Mammalian display platform for multispecific antigen binding proteins |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| EP4536836A1 (en) | 2022-06-07 | 2025-04-16 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024033332A1 (en) | 2022-08-08 | 2024-02-15 | Immatics Biotechnologies Gmbh | Guided positional scanning method |
| CN120202015A (zh) | 2022-09-14 | 2025-06-24 | Cdr-生物科技股份有限公司 | Mage-a4肽双重t细胞衔接子 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| US12134647B2 (en) | 2023-01-06 | 2024-11-05 | Immunocore Limited | Binding molecules |
| AU2024206446A1 (en) | 2023-01-06 | 2025-07-10 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
| WO2025008513A1 (en) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| WO2025021968A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| TW202530269A (zh) * | 2023-10-27 | 2025-08-01 | 大陸商北京可瑞生物科技有限公司 | 基於ｔ細胞受體的多特異性多肽分子及其組合物和用途 |
| WO2025094054A1 (en) * | 2023-11-01 | 2025-05-08 | Immunocore Limited | Method for purifying small multi-domain proteins |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| GB202320012D0 (en) * | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159940A1 (en) * | 2013-03-14 | 2014-10-02 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| WO2016184592A1 (en) * | 2015-05-19 | 2016-11-24 | Klinikum Rechts Der Isar Der Tu München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| WO2017070608A1 (en) * | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| WO2017109496A1 (en) * | 2015-12-22 | 2017-06-29 | Immunocore Limited | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| ES2327905T3 (es) | 2001-10-01 | 2009-11-05 | Dyax Corp. | Vectores de presentacion eucariotas multi-cadena y usos de los mismos. |
| EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
| WO2006103429A2 (en) | 2005-04-01 | 2006-10-05 | Medigene Limited | High affinity hiv t cell receptors |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| SI2002003T1 (sl) | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| CA2711806A1 (en) | 2008-01-11 | 2009-07-16 | Morphosys Ag | Display vectors and methods and uses thereof |
| EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| US20120294857A1 (en) | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| TWI807362B (zh) | 2010-11-30 | 2023-07-01 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| SG193023A1 (en) | 2011-02-11 | 2013-10-30 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| WO2013026837A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| WO2014083004A1 (en) | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| MX2015010843A (es) | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Moleculas biespecificas de union al antigeno que activan celulas t. |
| AU2014222779B2 (en) | 2013-02-26 | 2018-08-30 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
| PL3074424T3 (pl) | 2013-11-27 | 2025-06-09 | Zymeworks Bc Inc. | Bispecyficzne konstrukty wiążące antygen ukierunkowane na her2 |
| CN112390883A (zh) | 2013-12-17 | 2021-02-23 | 基因泰克公司 | 抗cd3抗体及使用方法 |
| AU2015236052B2 (en) | 2014-03-25 | 2018-05-10 | Boehringer Ingelheim Animal Health USA Inc. | Immunological compositions containing attenuated Histophilus somni |
| KR102523934B1 (ko) | 2014-07-24 | 2023-04-20 | 2세븐티 바이오, 인코포레이티드 | Bcma 키메릭 항원 수용체 |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| SG11201702976TA (en) * | 2014-11-20 | 2017-05-30 | Hoffmann La Roche | T cell activating bispecific antigen binding molecules agiant folr1 and cd3 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| EP3270937A4 (en) | 2015-03-26 | 2018-09-12 | The Trustees Of Dartmouth College | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| EP3359565A1 (en) | 2015-10-09 | 2018-08-15 | Immatics Biotechnologies GmbH | Anti-wt1/hla-specific antibodies |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| CN114634569B (zh) | 2016-04-15 | 2024-08-20 | 达特茅斯大学理事会 | 高亲和力b7-h6抗体和抗体片段 |
| KR102436129B1 (ko) | 2016-06-17 | 2022-08-26 | 메디진 이뮤노테라피스 게엠바하 | T 세포 수용체 및 이의 용도 |
| BR112018076555A2 (pt) | 2016-06-27 | 2019-04-02 | Procter & Gamble | aparelho e método para avaliar o tratamento de sensibilidade dentária por produto para tratamento bucal |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| US11325961B2 (en) | 2016-08-05 | 2022-05-10 | Tohoku University | Natural killer cell function enhancer |
| WO2018050902A2 (en) | 2016-09-15 | 2018-03-22 | Quadrucept Bio Limited | Multimers, tetramers & octamers |
| CN106831996B (zh) * | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| IL270897B2 (en) | 2017-06-01 | 2024-06-01 | Univ Stuttgart | Heterodimerizing ig domains |
| LT3652215T (lt) | 2017-07-14 | 2021-05-25 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| WO2019047932A1 (zh) | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| EP3747456A4 (en) | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
| BR112020023195A2 (pt) | 2018-05-14 | 2021-09-28 | Immunocore Limited | Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020057610A1 (en) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| JP2022541181A (ja) | 2019-07-15 | 2022-09-22 | ネオジン セラピューティクス ビー．ブイ． | Ｔｃｒ遺伝子の単離方法 |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CA3149939A1 (en) | 2019-09-06 | 2021-03-11 | Stephen J. Demarest | Proteins comprising t-cell receptor constant domains |
| CA3155728A1 (en) | 2019-09-25 | 2021-04-01 | Universitat Stuttgart | Trivalent binding molecules |
| AU2020355253A1 (en) | 2019-09-27 | 2022-03-24 | Agenus Inc. | Heterodimeric proteins |
| KR20220098379A (ko) | 2019-11-15 | 2022-07-12 | 그릿스톤 바이오, 인코포레이티드 | 공유 네오항원을 표적으로 하는 항원-결합 단백질 |
| BR112022009707A2 (pt) | 2019-11-18 | 2022-08-09 | BioNTech SE | Receptores de tcr prame e usos dos mesmos |
| EP4077370A4 (en) | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| WO2021188601A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| EP4121079A4 (en) | 2020-03-16 | 2024-10-30 | Angeles Therapeutics, Inc. | NEW ANTIGEN-BINDING DOMAINS AND SYNTHETIC ANTIGEN RECEPTORS |
| WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
| CN116171165A (zh) | 2020-06-10 | 2023-05-26 | 墨尔本大学 | Hiv-1抗体 |
| JP2023536100A (ja) | 2020-07-27 | 2023-08-23 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド |
| WO2022076788A1 (en) | 2020-10-09 | 2022-04-14 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (en) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| AU2021408160A1 (en) | 2020-12-21 | 2023-06-29 | Zymeworks Bc Inc. | Stabilized tcr constructs and methods of use |
| EP4297769A2 (en) | 2021-02-19 | 2024-01-03 | Preet M. Chaudhary | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2018
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en not_active Ceased
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en not_active Abandoned
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Ceased
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro unknown
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en not_active Ceased
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 AU AU2018298881A patent/AU2018298881B2/en active Active
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro unknown
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 KR KR1020207004219A patent/KR102833184B1/ko active Active
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt not_active Application Discontinuation
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh not_active IP Right Cessation
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh not_active IP Right Cessation
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en active Pending
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
-
2025
- 2025-06-17 US US19/240,392 patent/US20250361300A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159940A1 (en) * | 2013-03-14 | 2014-10-02 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| WO2016184592A1 (en) * | 2015-05-19 | 2016-11-24 | Klinikum Rechts Der Isar Der Tu München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| WO2017070608A1 (en) * | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| WO2017109496A1 (en) * | 2015-12-22 | 2017-06-29 | Immunocore Limited | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250361300A1 (en) | Improved dual specificity polypeptide molecule | |
| HK40071054A (en) | Improved dual specificity polypeptide molecule | |
| HK40003407B (en) | Improved dual specificity polypeptide molecule | |
| HK40003407A (en) | Improved dual specificity polypeptide molecule | |
| IL272045B2 (en) | A polypeptide molecule with dual-purpose specificity | |
| HK40029654A (en) | Improved dual specificity polypeptide molecule | |
| HK40029654B (en) | Improved dual specificity polypeptide molecule | |
| EA043129B1 (ru) | Усовершенствованная молекула полипептида с двойной специфичностью | |
| EA043319B1 (ru) | Усовершенствованная молекула полипептида с двойной специфичностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |